President-elect Donald Trump has put forward a formal pick for the top spot at the U.S. Food and Drug Administration. | ...

For many biopharmas, it takes years of hard work to transition from being a clinical-stage drugmaker to a commercial one.

While Johnson & Johnson hopes to soon resolve more than 60,000 talc lawsuits with an $8 billion bankruptcy settlement in the ...

Every year, Fierce’s pharma, biotech, and medtech teams come together to spotlight some of the fiercest women in life s | ...

For Big Pharma, recent headlines out of China suggest multinational drugmakers are facing their share of challenges in the ...

New York-based health comms agency Calcium+Company is living up to its name, strengthening the bones of its business with the ...

Australia’s CSL is winding down operations at a cell and gene therapy R&D site in California. Kyowa Kirin inked a commercialization and development deal with Kuro Oncology. Plus more.

As the biopharma industry braces for a second term under President-elect Donald Trump, speculation is swirling around the ...

As he introduced Novartis’ meet-the-management event Thursday in London, CEO Vas Narasimhan hammered home Novartis’ status as ...

While president-elect Donald Trump has already made his leadership picks for the Department of Health and Human Services (HHS ...